Skip to main content

Advertisement

SpringerLink
Log in

Does botulinum toxin A reduce adductor muscle spasticity in children with cerebral palsy?

  • Practice Point
  • Published:

From Nature Clinical Practice Neurology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Carpenter EB and Seitz DG (1980) Intramuscular alcohol as an aid in management of spastic cerebral palsy. Dev Med Child Neurol 22: 497–501

    Article  CAS  Google Scholar 

  2. Koman LA et al. (1993) Management of cerebral palsy with botulinum-A toxin: preliminary investigation. J Pediatr Orthop 13: 489–495

    Article  CAS  Google Scholar 

  3. Boyd RN et al. (2001) The effect of botulinum toxin type A and a variable hip abduction orthosis on gross motor function: a randomized controlled trial. Eur J Neurol 8 (Suppl 5): 109–119

    Article  Google Scholar 

  4. Koman LA et al. (2003) Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin. Paediatr Drugs 5: 11–23

    Article  Google Scholar 

  5. Pidcock FS et al. (2005) Hip migration percentage in children with cerebral palsy treated with botulinum toxin type A. Arch Phys Med Rehabil 86: 431–435

    Article  Google Scholar 

  6. Willenborg MJ et al. (2002) Technique for iliopsoas ultrasound-guided active electromyography-directed botulinum A toxin injection in cerebral palsy. J Pediatr Orthop 22: 165–168

    PubMed  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Martina Habeck, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor at the Department of Orthopaedic Surgery, Wake Forest University Health Sciences, Winston-Salem, NC, USA

    L Andrew Koman

Authors
  1. L Andrew Koman
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author has received research support and an honorarium from Allergan; he has also received research support from Solstice Neurosciences, and he is the medical director of SciMed, an LLC that licensed Wake Forest's intellectual property on botulinum toxin products.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koman, L. Does botulinum toxin A reduce adductor muscle spasticity in children with cerebral palsy?. Nat Rev Neurol 2, 414–415 (2006). https://doi.org/10.1038/ncpneuro0244

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0244

  • Springer Nature Limited

Search

Navigation